Department of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Department of Acupuncture and Moxibustion, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Biomed Res Int. 2022 Aug 8;2022:3915402. doi: 10.1155/2022/3915402. eCollection 2022.
Current studies on the relationship between XRCC3 rs861539 polymorphism and ovarian cancer risk have been inconsistent. Therefore, we performed a meta-analysis to explore their association.
Six electronic databases (PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, and China Wanfang Database) were searched for relevant studies published before December 2021. Meta-analysis, subgroup analysis, sensitivity analysis, and publication bias analysis were performed using Stata software 16.0. Trial sequential analysis (TSA) was performed using TSA 0.9.5.10 Beta software.
A total of 12 studies were included in 9 literatures, comprising 4,634 cases of ovarian cancer and 7,381 controls. After Bonferroni correction, the meta-analysis showed an association between XRCC3 rs861539 polymorphism and ovarian cancer risk in the heterozygote model and the dominant model (GA vs. GG: OR = 0.88, 95%CI = 0.81-0.96, = 0.003; GG vs. GA+AA: OR = 0.89, 95%CI = 0.82-0.96, = 0.004). In an ethnically stratified subgroup analysis, XRCC3 rs861539 was shown to reduce the risk of ovarian cancer in Caucasian in the heterozygote model and the dominant model (GA vs. GG: OR = 0.88, 95%CI = 0.81-0.96, = 0.004; GG vs. GA+AA: OR = 0.88, 95%CI = 0.81-0.96, = 0.004). In the control source and detection method stratified subgroup analysis, hospital-based studies and PCR-RFLP-based studies were found to increase ovarian cancer risk (GG vs. AA: OR = 1.30, 95%CI = 1.05-1.62, = 0.016; GG vs. AA: OR = 1.31, 95%CI = 1.06-1.62, = 0.013).
This meta-analysis showed a significant association between XRCC3 rs861539 polymorphism and ovarian cancer risk, especially in Caucasians. Large-scale multicenter case-control studies in more different regions will be needed in the future.
目前关于 XRCC3 rs861539 多态性与卵巢癌风险之间关系的研究结果并不一致。因此，我们进行了一项荟萃分析来探讨它们之间的相关性。
检索了 PubMed、Embase、Web of Science、Cochrane Library、中国知网和万方数据库等 6 个电子数据库，收集截至 2021 年 12 月发表的相关研究。使用 Stata 软件 16.0 进行荟萃分析、亚组分析、敏感性分析和发表偏倚分析。采用 TSA 0.9.5.10 Beta 软件进行试验序贯分析（TSA）。
共有 9 篇文献中的 12 项研究被纳入，共包括 4634 例卵巢癌病例和 7381 例对照。经过 Bonferroni 校正后，荟萃分析显示 XRCC3 rs861539 多态性与卵巢癌风险在杂合子模型和显性模型中存在关联（GA 与 GG：OR=0.88，95%CI=0.81-0.96， = 0.003；GG 与 GA+AA：OR=0.89，95%CI=0.82-0.96， = 0.004）。在按种族分层的亚组分析中，XRCC3 rs861539 显示在杂合子模型和显性模型中降低了高加索人群患卵巢癌的风险（GA 与 GG：OR=0.88，95%CI=0.81-0.96， = 0.004；GG 与 GA+AA：OR=0.88，95%CI=0.81-0.96， = 0.004）。在按对照来源和检测方法分层的亚组分析中，发现医院为基础的研究和基于 PCR-RFLP 的研究增加了卵巢癌的风险（GG 与 AA：OR=1.30，95%CI=1.05-1.62， = 0.016；GG 与 AA：OR=1.31，95%CI=1.06-1.62， = 0.013）。
这项荟萃分析表明，XRCC3 rs861539 多态性与卵巢癌风险之间存在显著关联，尤其是在高加索人群中。未来需要在更多不同地区开展大规模多中心病例对照研究。
